 |
 |
|
Rapamune |
|
The Health Insurance Portability and Accountability Act of 1996 HIPAA ; has been discussed in the past three editions of this Newsletter. By the time you receive this Newsletter, the compliance deadline of April 14, 2003, for meeting the HIPAA privacy regulation may have already passed. On February 20, 2003, the United States Department of Health and Human Services HHS ; published the final HIPAA security standards in the Federal Register. The compliance date for the security standard will be April 20, 2005. For most pharmacy operations, security rules could surpass privacy in terms of time, money, and resources needed to comply. Pharmacy operators may wish to first contact their software vendor and find out how many of the security requirements the vendor will help implement and how many will have to be done alone or with assistance from a consultant. Just like the privacy regulation, the security regulation also requires significant documentation of policies and procedures. Also like the privacy regulation, the security regulation requires providers to appoint a security official, who may be the same person as your privacy official. In addition to the final security standards, HHS also published some minor changes made to the transaction rule. Receptor V1 ; antagonist lowered blood pressure BP ; and attenuated the increase in preproET-1 gene expression observed in mesenteric arteries of DOCA-salt hypertensive rats. Intengan et al. also demonstrated that the enhanced ET-1 gene expression observed in rats treated with the DOCA-salt regimen was absent in the Brattleboro rat 11 ; , a rat homozygous for diabetes insipidus with no detectable levels of AVP in plasma 20 ; . Thus there is a strong association between V1 receptor activation by AVP and ET-1 gene expression, and this association is correlated with the development of DOCA-salt hypertension. However, the possibility that the ET system contributes directly to the hemodynamic actions of AVP in the DOCA-salt model of hypertension has not been studied. The purpose of this study was to examine this issue by recording hemodynamic responses to AVP in the conscious unrestrained DOCA-salt hypertensive rat both when the ET system was functional and when it was blocked with the nonpeptide mixed ETA ETB receptor antagonist bosentan. To quantify the contribution of ET to the effects of AVP at the level of the resistance function of the circulation, we determined the changes in total peripheral resistance TPR ; by recording BP with radiotelemetry devices and cardiac output CO ; with ultrasonic flowprobes. For comparison, the responses to ANG II were also evaluated. Kidney stones have been reported in patients taking REYATAZ atazanavir sulfate ; . If you develop signs or symptoms of kidney stones pain in your side, blood in your urine, pain when you urinate ; tell your healthcare provider promptly. some patients with hemophilia have increased bleeding problems with protease inhibitors like REYATAZ. changes in body fat. These changes may include an increased amount of fat in the upper back and neck "buffalo hump" ; , breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time. Other common side effects of REYATAZ taken with other anti-HIV medicines include nausea; headache; stomach pain; vomiting; diarrhea; depression; fever; dizziness; trouble sleeping; numbness, tingling, or burning of hands or feet; and muscle pain. What important information should I know about taking REYATAZ with other medicines? Do not take REYATAZ if you take the following medicines not all brands may be listed; tell your healthcare provider about all the medicines you take ; . REYATAZ may cause serious, life-threatening side effects or death when used with these medicines. Ergot medicines: dihydroergotamine, ergonovine, ergotamine, and methylergonovine such as CAFERGOT , MIGRANAL, D.H.E. 45, ergotrate maleate, METHERGINE, and others used for migraine headaches ; . HALCION triazolam, used for insomnia ; . VERSED midazolam, used for sedation ; . ORAP pimozide, used for Tourette's disorder ; . PROPULSID cisapride, used for certain stomach problems ; . Do not take the following medicines with REYATAZ because of possible serious side effects: CAMPTOSAR irinotecan, used for cancer ; . CRIXIVAN indinavir, used for HIV infection ; . Both REYATAZ and CRIXIVAN sometimes cause increased levels of bilirubin in the blood. Cholesterol-lowering medicines MEVACOR lovastatin ; or ZOCOR simvastatin ; . Do not take the following medicines with REYATAZ because they may lower the amount of REYATAZ in your blood. This may lead to an increased HIV viral load. Resistance to REYATAZ or cross-resistance to other HIV medicines may develop: Rifampin also known as RIMACTANE, RIFADIN, RIFATER, or RIFAMATE, used for tuberculosis ; . St. John's wort Hypericum perforatum ; , an herbal product sold as a dietary supplement, or products containing St. John's wort. "Proton-pump inhibitors" used for indigestion, heartburn, or ulcers such as AcipHex rabeprazole ; , NEXIUM esomeprazole ; , PREVACID lansoprazole ; , PRILOSEC omeprazole ; , or PROTONIX pantoprazole ; . Do not take the following medicine if you are taking REYATAZ and NORVIR together. VFEND voriconazole ; . The following medicines may require your healthcare provider to monitor your therapy more closely: CIALIS tadalafil ; , LEVITRA vardenafil ; , or VIAGRA sildenafil ; . REYATAZ may increase the chances of serious side effects that can happen with CIALIS, LEVITRA, or VIAGRA. Do not use CIALIS, LEVITRA, or VIAGRA while you are taking REYATAZ unless your healthcare provider tells you it is okay. LIPITOR atorvastatin ; . There is an increased chance of serious side effects if you take REYATAZ with this cholesterol-lowering medicine. Medicines for abnormal heart rhythm: CORDARONE amiodarone ; , lidocaine, quinidine also known as CARDIOQUIN, QUINIDEX, and others ; . VASCOR bepridil, used for chest pain ; . COUMADIN warfarin ; . Tricyclic antidepressants such as ELAVIL amitriptyline ; , NORPRAMIN desipramine ; , SINEQUAN doxepin ; , SURMONTIL trimipramine ; , TOFRANIL imipramine ; , or VIVACTIL protriptyline ; . Medicines to prevent organ transplant rejection: SANDIMMUNE or NEORAL cyclosporin ; , RAPAMUNE sirolimus ; , or PROGRAF tacrolimus ; . The antidepressant trazodone DESYREL and others ; . Fluticasone propionate ADVAIR, FLONASE, FLOVENT ; , given by nose or inhaled to treat allergic symptoms or asthma. Your doctor may choose not to keep you on fluticasone, especially if you are also taking NORVIR. The following medicines may require a change in the dose or dose schedule of either REYATAZ or the other medicine: FORTOVASE, INVIRASE saquinavir ; . NORVIR ritonavir ; . SUSTIVA efavirenz ; . Antacids or buffered medicines. VIDEX didanosine ; . VIREAD tenofovir disoproxil fumarate ; . MYCOBUTIN rifabutin ; . Calcium channel blockers such as CARDIZEM or TIAZAC diltiazem ; , COVERA-HS or ISOPTIN SR verapamil ; , and others. BIAXIN clarithromycin ; . Medicines for indigestion, heartburn, or ulcers such as AXID nizatidine ; , PEPCID AC famotidine ; , TAGAMET cimetidine ; , or ZANTAC ranitidine ; . Women who use birth control pills or "the patch" should choose a different kind of contraception. REYATAZ may affect the safety and effectiveness of birth control pills or the patch. Talk to your healthcare provider about choosing an effective contraceptive. Remember: 1. Know all the medicines you take. 2. Tell your healthcare provider about all the medicines you take. 3. Do not start a new medicine without talking to your healthcare provider. How should I store REYATAZ? Store REYATAZ Capsules at room temperature, 59 to 86 F not store this medicine in a damp place such as a bathroom medicine cabinet or near the kitchen sink. Keep your medicine in a tightly closed container. Throw away REYATAZ when it is outdated or no longer needed by flushing it down the toilet or pouring it down the sink. General information about REYATAZ This medicine was prescribed for your particular condition. Do not use REYATAZ for another condition. Do not give REYATAZ to other people, even if they have the same symptoms you have. It may harm them. Keep REYATAZ and all medicines out of the reach of children and pets. This summary does not include everything there is to know about REYATAZ. Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Remember no written summary can replace careful discussion with your healthcare provider. If you would like more information, talk with your healthcare provider or you can call 1-800-321-1335. What are the ingredients in REYATAZ? Active Ingredient: atazanavir sulfate Inactive Ingredients: Crospovidone, lactose monohydrate milk sugar ; , magnesium stearate, gelatin, FD&C Blue #2, titanium dioxide, black iron oxide, red iron oxide, and yellow iron oxide. VIDEX and REYATAZ are registered trademarks of Bristol-Myers Squibb Company. COUMADIN and SUSTIVA are registered trademarks of Bristol-Myers Squibb Pharma Company. DESYREL is a registered trademark of Mead Johnson and Company. Other brands listed are the trademarks of their respective owners and are not trademarks of Bristol-Myers Squibb Company. Rapamune for menSelective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 2002; 63: 733736 Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256259 Tohen M, Vieta E, Ketter T, et al. Olanzapine and olanzapine-fluoxetine combination OFC ; in the treatment of bipolar depression. Presented at the 155th annual meeting of the American Psychiatric Association; May 18, 2002; Philadelphia, Pa Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. J Psychiatry 2001; 158: 131134 McCall WV. Electroconvulsive therapy in the era of modern psychopharmacology. Int J Neuropsychopharmacol 2001; 4: 315324 Thase ME, Friedman ES, Howland RH. Management of treatmentresistant depression: psychotherapeutic perspectives. J Clin Psychiatry. Protonix protopic provigil pseudoephedrine chlorpheniramine codeine soln, 30 2 10 per 5 ml novahistine dh ; pseudoephedrine guaifenesin ext-release caps, 60 300; ext-release tabs, 45 600, 60 pseudoephedrine guaifenesin ext-release tabs, 120 600 zephrex la ; pulmicort respules pulmozyme pyrazinamide pyridostigmine tabs mestinon ; quadramet quinidine gluconate ext-release tabs, 324 mg quinidine sulfate quinidine sulfate ext-release tabs, 300 mg ranitidine zantac ; rapamune rebif renagel repronex pa requip rescriptor reserpine restoril 5 mg retrovir reyataz ribavirin caps rebetol ; ridaura rifampin rilutek rimantadine tabs flumadine ; risperdal risperdal m-tab rituxan roferon-a roxicet soln salagen salsalate sandimmune sandostatin lar depot selegiline caps eldepryl ; selegiline tabs selenium sulfide 5% selsun ; sensipar serentil serevent diskus seroquel silver sulfadiazine silvadene and raptiva. Everolimus Certican , Novartis Pharma AG, Basel, Switzerland ; and sirolimus Rapamune , Wyeth Pharmaceuticals, USA ; belong to the novel class of immunosuppressant agents known as proliferation signal inhibitors PSIs ; mammalian target of rapamycin mTOR ; inhibitors. Both everolimus and sirolimus are macrolide derivatives with similar chemical structures. However, despite the similarities, there are important pharmacokinetic differences between the two molecules. Notably, the half-life of everolimus 28 h ; is considerably shorter than that of sirolimus 62 h ; and, owing to differences in treatment regimens, everolimus reaches steady state in 4 days, compared with 6 days for sirolimus [1]. This review will summarize the clinical data for everolimus and assess its clinical role in renal transplant recipients, including de novo and maintenance patients. Figure 4. Top selling groups of pharmaceuticals and raspberry. Administeredactivity per gram and as percentadministeredactiv ity per 1%animal weight. The tissue and organ concentrations. Rapamune productsRapamune Sirolimus ; is an immunosuppressive drug that helps prevent your body from rejecting the new kidney. It is also used in some cases to treat acute rejection. It is taken in combination with cyclosporine and prednisone. Rapamune comes in liquid and tablet form, either 1 mg or 5 mg dose concentrations. Liquid Rapamune should be mixed in orange juice, Tang, or water only. Mix this in a glass and do not leave it sitting. Rapamune is taken once daily, 4 hours after the morning dose of Neoral. Rapamune should be protected from light. The liquid should be kept in the refrigerator and the tablets should be stored in a cool, dry area not refrigerated ; . Side effects: Rapamune can cause a low white blood cell count, which will make you more susceptible to infections. It may also cause a decreased platelet count, which can make you bleed more easily. Dosage adjustment may reduce both of these side effects. Rapamune can also cause indigestion, diarrhea, nose bleeds, headaches, joint pains, and elevated cholesterol and triglyceride levels. Kong uenza to spend rapamune much has reteplase to make rev-eyes savings and refresh. 11.Gorgun G, Foss FM. Induction of apoptosis in lymphoid leukemia cells: Differential effects of RAR and RXR retinoids with dexamethasone. Poster presented at The American Society of Hematology 42nd Meeting San Francisco, California, December 1-5, 2000. Rapamune is the first of a distinctive class of immunosuppressants known as mtor inhibitors and relenza. Prostaglandins are lipid molecules with a range of biological activities, including the regulation of immune responses. In mammalian systems they are synthesized from arachidonic acid, which is formed from phospholipids via the action of two cyclooxygenase COX ; isoenzymes, COX-1 and COX-2 Dannhardt & Kiefer, 2001; Harris et al., 2002 ; . Prostaglandins are now known to be produced by various eukaryotic micro-organisms as well as by mammalian cells, and they have recently been identified in pathogenic fungi Noverr et al., 2001, 2002, 2003 ; . Culture supernatants from both Candida albicans and Cryptococcus neoformans contained prostaglandins, and treatment of either yeast with the COXinhibitor indomethacin significantly reduced cell viability Noverr et al., 2001 ; . Purified fungal prostaglandin, partially characterized as a PGE prostaglandin E ; series lipid, was shown to enhance germ tube formation by C. albicans, and affected chemokine production by mammalian cells Noverr et al., 2001 ; . Little is known about the role of prostaglandins in fungal biology. They may function as regulators of gene expression, possibly in relation to dimorphism in C. albicans. Considering their known effects on mammalian cell biology, prostaglandins secreted by pathogenic fungi could also promote colonization and chronic infection by these organisms. Colonization frequently involves the formation of a biofilm on host surfaces Douglas, 2003 ; . Recently, we investigated the effects of various COX inhibitors on C. albicans biofilms Alem & Douglas, 2004 ; . Etodolac, diclofenac, and most notably aspirin, dramatically decreased biofilm formation by. Sirolimus rapamune solution, oral 1 mg ml tablets 1 mg tablets 2 mg indicates canadian trade name and remicade. Related drugs by condition organ transplant - rejection prophylaxis cellcept , azathioprine , cyclosporine , prograf , imuran , rapamune , more. The flow-rate of unstimulated whole saliva, the volume of saliva in the mouth before VMAX ; and after RESID ; swallowing and the surface area of the mouth were measured to determine the average thickness of the salivary film in five-year-old children with primary dentitions. In 30 subjects of each gender, RESID was measured by a dilution technique of the potassium in unstimulated saliva. VMAX was calculated as the total of RESID plus the volume normally swallowed the unstimulated salivary flow-rate divided by the swallowing frequency ; . From these children, 10 subjects of each gender who had no missing teeth were selected and impressions taken to determine the surface area of the mouth. Aluminum foil, of known weight per unit area, was adapted to the stone models of different regions of the mouth, and the surface areas were calculated from the weights of foil. The unstimulated salivary flow-rate was 0.22 + 0.14 mL min, the mean values of RESID and VMAX were 0.38 + 0.11 mL and 0.50 + 0.15 mL, respectively, and the mean total surface area of the mouth was 117.6 + 7.6 cm'. These were no significant differences in these values due to gender. From these values, it was calculated that the average thickness of the salivary film in the mouth varied between 0.06 and 0.09 mm. Although the values of salivary flow-rate, RESID and VMAX were much lower than those reported for adults, the average thickness of the salivary film was very similar to that in adults and remodulin.
College Council Gold Medal for being Best Graduate of year 2005 in MBBS. Silver Medal for being First in Aggregate in Final Prof. MBBS 2005. Silver Medal for being First in Surgery in Final Prof. MBBS 2005. Silver Medal for being First in Medicine in Final Prof. MBBS 2005. Silver Medal for being First in Aggregate in 2nd Prof. MBBS 2003. Silver Medal for being First in Microbiology in 2nd Prof. MBBS 2003. Silver Medal for being First in Forensic Medicine in 2nd Prof. MBBS 2003. Most patients with a malignant glioma will experience a tumor recurrence. While there have been exciting advances in the treatment of these tumors at the time of initial diagnosis, the treatment options for recurrent tumors has been more limited. Neuro oncologists at the Preston Robert Tisch Brain Tumor Center at Duke University are testing several chemotherapy protocols to treat recurrent malignant glioma, two of which are being used for Upper Michigan Brain Tumor Center patients. The first protocol is CPT-11 and Avastin. CPT-11 also known as Camptosar or irinotecan ; is a chemotherapy agent that has been used to treat patients with colon cancer. It is administered intravenously with the main side effect being diarrhea. Avastin or bevacizumab ; is a monoclonal antibody that inhibits vascular endothelial growth factor VEGF ; . In order for tumors to grow, they need a large blood supply. Tumors secrete VEGF in order to attract new blood vessels to the tumor. Avastin helps block this pathway, preventing new blood vessels from growing to the tumor. Avastin is used in colon cancer and nonsmall cell lung cancer. It is administered intravenously with the main side effects being gastrointestinal perforation and bleeding within the tumor. A second protocol is Tarceva and Rapamune. Tarceva or erlontinib ; is an oral chemotherapy agent that inhibits EGFR. EGFR is a cell surface receptor that promotes cell division. Rash and diarrhea are the most common side effects. Tarceva has activity against a variety of cancers. Rapamune or sirolimus ; is an oral chemotherapy agent. Rapamune inhibits an enzyme called mTOR. This inhibition prevents a cell from dividing. We have treated several Upper Peninsula patients with the CPT-11 and Avastin protocol. Other UMBTC patients from have been enrolled in clinical trials at Duke and renova and rapamune. L. Liu1, W. Zhu2, Z-S. Zhang3, T. Yang4, A. Grant3 , G. Oxford2 and S. A. Simon1, 4 Departments of Anesthesiology1 Medicine3, and Neurobiology4, Duke University, Durham, NC 27710 and Department of Cell and Molecular Physiology2, University of North Carolina, Chapel Hill, NC 27599. |
